Zacks Small Cap Issues Optimistic Estimate for ABEO Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Research analysts at Zacks Small Cap lifted their Q3 2025 earnings per share (EPS) estimates for Abeona Therapeutics in a report released on Monday, August 18th. Zacks Small Cap analyst D. Bautz now expects that the biopharmaceutical company will post earnings of ($0.17) per share for the quarter, up from their prior estimate of ($0.18). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at $0.10 EPS.

Other analysts also recently issued reports about the company. Oppenheimer upped their price objective on Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Friday, August 15th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Monday. Stifel Nicolaus reduced their price objective on Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. Alliance Global Partners restated a “buy” rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Finally, Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 15th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $19.50.

Abeona Therapeutics Stock Up 1.6%

Shares of NASDAQ:ABEO opened at $7.11 on Thursday. The company has a quick ratio of 4.90, a current ratio of 6.73 and a debt-to-equity ratio of 0.09. Abeona Therapeutics has a 52-week low of $3.93 and a 52-week high of $7.54. The stock’s fifty day simple moving average is $6.28 and its 200-day simple moving average is $5.78. The company has a market capitalization of $364.60 million, a P/E ratio of 10.16 and a beta of 1.55.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $21.71 million.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. acquired a new stake in Abeona Therapeutics during the second quarter worth about $25,000. Legal & General Group Plc acquired a new stake in Abeona Therapeutics during the second quarter worth about $27,000. Twinbeech Capital LP acquired a new stake in Abeona Therapeutics during the fourth quarter worth about $58,000. Riverwater Partners LLC acquired a new stake in Abeona Therapeutics during the second quarter worth about $62,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at about $63,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Abeona Therapeutics news, SVP Brendan M. O’malley sold 17,428 shares of the company’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $102,128.08. Following the completion of the sale, the senior vice president directly owned 360,817 shares in the company, valued at $2,114,387.62. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Vishwas Seshadri sold 69,420 shares of the company’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $406,801.20. Following the sale, the chief executive officer owned 1,234,341 shares of the company’s stock, valued at $7,233,238.26. This represents a 5.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 231,626 shares of company stock valued at $1,430,587 in the last three months. Company insiders own 6.90% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.